Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors

This trial is testing a three-drug immunotherapy combination (triple checkpoint inhibitors) delivered via a procedure that targets the blood supply to liver tumors (hepatic arterial infusion) in patients with advanced solid tumors. The aim is to boost the immune system's attack on the cancer. **You may be eligible if...** - You are 18 or older with a confirmed cancer diagnosis - You have at least one tumor that can be measured on imaging - You are in reasonably good health (ECOG score less than 2) - Your liver, kidney, and blood counts are within acceptable ranges **You may NOT be eligible if...** - You are currently enrolled in another drug trial - You have uncontrolled fluid in the abdomen (ascites), confusion from liver disease, or bleeding from esophageal or stomach varices - You have another active cancer or history of malignancy - You are pregnant or breastfeeding - You have uncontrolled blood pressure, heart disease, or diabetes Talk to your doctor to see if this trial is right for you.